Cenerimod - Idorsia Pharmaceuticals

Drug Profile

Cenerimod - Idorsia Pharmaceuticals

Alternative Names: ACT-334441; lysosphingolipid receptor agonist - Idorsia; S1P1 receptor modulator - Idorsia; Second selective S1P1 receptor agonist - Idorsia; Sphingosine 1-phosphate receptor 1 agonists - Idorsia

Latest Information Update: 08 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Actelion Pharmaceuticals
  • Developer Idorsia Pharmaceuticals
  • Class Oxadiazoles; Pyridines; Small molecules
  • Mechanism of Action Lysosphingolipid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus

Most Recent Events

  • 01 Dec 2017 Cenerimod - Idorsia Pharmaceuticals receives Fast Track designation for Systemic lupus erythematosus [PO,Capsule] in USA
  • 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
  • 16 Jun 2017 Actelion Pharmaceuticals spun off its drug discovery operations and early-stage clinical development assets into a newly created company, Idorsia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top